Santarus, Inc., a specialty pharmaceutical company, engages in the acqusition, development, and commercialization of proprietary products and therapies that treat gastrointestinal diseases and disorders, including gastroesophageal reflux disease (GERD) in the United States. It offers Zegerid family of products, which are proprietary immediate-release formulations that combine omeprazole, a proton pump inhibitor (PPI), and one or more antacids. The company's products are prescribed for the treatment of upper gastrointestinal diseases and disorders, including heartburn and other symptoms associated with GERD, erosive esophagitis, upper gastrointestinal bleeding, and gastric and duodenal ulcers. Santarus offers products in capsule, powder for oral suspension, and chewable tablet dosage forms. It sells its approved products to pharmaceutical wholesalers, who in turn distribute the products to retail pharmacies, mail order pharmacies, hospitals, and other institutional customers. Santarus has a strategic alliance with Schering-Plough Healthcare Products, Inc. to develop, manufacture, and sell over the counter products with the lower dosage strength of 20 mg of omeprazole in the United States and Canada; and a license agreement with the University of Missouri for its patents and pending patent applications relating to specific formulations of PPIs with antacids and other buffering agents. The company was founded in 1996 and is headquartered in San Diego, California.